According to GuruFocus Insider Data, these are the largest CFO buys during the past week. The overall trend of CFOs is illustrated in the chart below:
E. W. Scripps Company (SSP, Financial): Senior Vice President, CFO and Treasurer Timothy M. Wesolowski Bought 26,700 Shares
Senior Vice President, CFO and Treasurer of E. W. Scripps Company (SSP) Timothy M. Wesolowski bought 26,700 shares on 03/13/2012 at an average price of $9.4. E. W. Scripps Company is a diversified media company operating in three reportable segments: newspapers, broadcast television and category television. E. W. Scripps Company has a market cap of $508.9 million; its shares were traded at around $9.77 with and P/S ratio of 0.7.
The E.W. Scripps Company reported operating results for the fourth quarter of 2011. Consolidated revenues were $197 million, a decrease of 10.4 percent from $220 million in the fourth quarter of 2010. Total operating expenses were $180 million, unchanged from the prior year.
Senior Vice President, CFO and Treasurer Timothy M. Wesolowski, Director Paul K. Scripps, and Director John H. Burlingame sold of SSP stock.
Cytori Therapeutics (CYTX, Financial): CFO Mark E. Saad Bought 10,000 Shares
CFO of Cytori Therapeutics (CYTX) Mark E. Saad bought 10,000 shares on 03/14/2012 at an average price of $2.55. Cytori Therapeutics Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. Cytori Therapeutics has a market cap of $145 million; its shares were traded at around $3.13 with and P/S ratio of 17.6.
Cytori Therapeutics reported its third quarter 2011 business update and financial results. Product revenues for the third quarter of 2011 increased to $2.1 million, compared to $1.5 million in the third quarter of 2010. Net cash used in operating activities improved to $7.9 million in the third quarter of 2011 from $9.0 million in the second quarter of 2011.
CEO Christopher J. Calhoun, CFO Mark E. Saad, and President Marc H. Hedrick bought shares of CYTX stock.
Agilysys Inc. (AGYS, Financial): Senior Vice President, CFO and Treasurer Robert R. Ellis Bought 10,000 Shares
Senior Vice President, CFO and Treasurer of Agilysys Inc. (AGYS) Robert R. Ellis bought 10,000 shares on 03/06/2012 at an average price of $8. Agilysys Inc. is a provider of innovative IT solutions to corporate and public-sector customers, with special expertise in select vertical markets, including retail and hospitality. Agilysys Inc. has a market cap of $180.1 million; its shares were traded at around $9.02 with and P/S ratio of 0.3.
Agilysys, Inc. announced unaudited financial results for the fiscal 2012 third quarter and nine months ended December 31, 2011. Total net sales declined 12.6% to $51.6 million, compared with $59.0 million in the same prior-year period. The net loss from continuing operations for the quarter was $5.8 million, or $0.26 per share, compared with a loss from continuing operations of $2.3 million, or $0.10 per share, last year.
President and CEO Jim Dennedy, Senior Vice President, CFO and Treasurer Robert R. Ellis, and Senior Vice President, GC and Secretary Kyle C. Badger bought shares of AGYS stock.
Valeant Pharmaceuticals International (VRX, Financial): CFO Howard Bradley Schiller Bought 9,200 Shares
CFO of Valeant Pharmaceuticals International (VRX) Howard Bradley Schiller bought 9,200 shares on 03/06/2012 at an average price of $53.53. Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. Valeant Pharmaceuticals International has a market cap of $17.11 billion; its shares were traded at around $53.64 with a P/E ratio of 20.7 and P/S ratio of 7.
Valeant Pharmaceuticals International, Inc. announced fourth quarter financial results for 2011. Total reported revenue was $688.4 million in the fourth quarter of 2011 as compared to $514.6 million in the fourth quarter of 2010. The Company reported net income of $55.9 million for the fourth quarter of 2011, or $0.18 per diluted share.
CFO Howard Bradley Schiller, EVP and CFO Howard Bradley Schiller, and Executive Vice President and CFO Howard Bradley Schiller bought shares of VRX stock.
Tianyin Pharmaceutical Co. (TPI, Financial): CFO, Director and CBDO James Jiayuan Tong Bought 5,000 Shares
CFO, Director and CBDO of Tianyin Pharmaceutical Co. (TPI) James Jiayuan Tong bought 5,000 shares on 03/14/2012 at an average price of $0.85. TIANYIN is a manufacturer and supplier of modernized Traditional Chinese Medicine in China. Tianyin Pharmaceutical Co. has a market cap of $23.5 million; its shares were traded at around $0.87 with a P/E ratio of 2.4 and P/S ratio of 0.3.
Tianyin Pharmaceutical Inc. announced financial results for the second quarter of Fiscal Year 2012. Net Income was $1.7 million for the quarter ended Dec. 31, 2011, as compared to the net income of $1.5 million for the first quarter of fiscal 2012. Sales for the quarter ended Dec. 31, 2011 was $18.2 million, a decrease of 28.0% as compared to $25.3 million for the quarter ended Dec. 31, 2010, but a slight gain from the first quarter of fiscal 2012 which was $17.5 million.
CEO, 10% Owner Guoqing Jiang, and CFO, Director and CBDO James Jiayuan Tong bought shares of TPI stock.
For the complete list of stocks that bought by their CFOs, go to: Insider Buys.
E. W. Scripps Company (SSP, Financial): Senior Vice President, CFO and Treasurer Timothy M. Wesolowski Bought 26,700 Shares
Senior Vice President, CFO and Treasurer of E. W. Scripps Company (SSP) Timothy M. Wesolowski bought 26,700 shares on 03/13/2012 at an average price of $9.4. E. W. Scripps Company is a diversified media company operating in three reportable segments: newspapers, broadcast television and category television. E. W. Scripps Company has a market cap of $508.9 million; its shares were traded at around $9.77 with and P/S ratio of 0.7.
The E.W. Scripps Company reported operating results for the fourth quarter of 2011. Consolidated revenues were $197 million, a decrease of 10.4 percent from $220 million in the fourth quarter of 2010. Total operating expenses were $180 million, unchanged from the prior year.
Senior Vice President, CFO and Treasurer Timothy M. Wesolowski, Director Paul K. Scripps, and Director John H. Burlingame sold of SSP stock.
Cytori Therapeutics (CYTX, Financial): CFO Mark E. Saad Bought 10,000 Shares
CFO of Cytori Therapeutics (CYTX) Mark E. Saad bought 10,000 shares on 03/14/2012 at an average price of $2.55. Cytori Therapeutics Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. Cytori Therapeutics has a market cap of $145 million; its shares were traded at around $3.13 with and P/S ratio of 17.6.
Cytori Therapeutics reported its third quarter 2011 business update and financial results. Product revenues for the third quarter of 2011 increased to $2.1 million, compared to $1.5 million in the third quarter of 2010. Net cash used in operating activities improved to $7.9 million in the third quarter of 2011 from $9.0 million in the second quarter of 2011.
CEO Christopher J. Calhoun, CFO Mark E. Saad, and President Marc H. Hedrick bought shares of CYTX stock.
Agilysys Inc. (AGYS, Financial): Senior Vice President, CFO and Treasurer Robert R. Ellis Bought 10,000 Shares
Senior Vice President, CFO and Treasurer of Agilysys Inc. (AGYS) Robert R. Ellis bought 10,000 shares on 03/06/2012 at an average price of $8. Agilysys Inc. is a provider of innovative IT solutions to corporate and public-sector customers, with special expertise in select vertical markets, including retail and hospitality. Agilysys Inc. has a market cap of $180.1 million; its shares were traded at around $9.02 with and P/S ratio of 0.3.
Agilysys, Inc. announced unaudited financial results for the fiscal 2012 third quarter and nine months ended December 31, 2011. Total net sales declined 12.6% to $51.6 million, compared with $59.0 million in the same prior-year period. The net loss from continuing operations for the quarter was $5.8 million, or $0.26 per share, compared with a loss from continuing operations of $2.3 million, or $0.10 per share, last year.
President and CEO Jim Dennedy, Senior Vice President, CFO and Treasurer Robert R. Ellis, and Senior Vice President, GC and Secretary Kyle C. Badger bought shares of AGYS stock.
Valeant Pharmaceuticals International (VRX, Financial): CFO Howard Bradley Schiller Bought 9,200 Shares
CFO of Valeant Pharmaceuticals International (VRX) Howard Bradley Schiller bought 9,200 shares on 03/06/2012 at an average price of $53.53. Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. Valeant Pharmaceuticals International has a market cap of $17.11 billion; its shares were traded at around $53.64 with a P/E ratio of 20.7 and P/S ratio of 7.
Valeant Pharmaceuticals International, Inc. announced fourth quarter financial results for 2011. Total reported revenue was $688.4 million in the fourth quarter of 2011 as compared to $514.6 million in the fourth quarter of 2010. The Company reported net income of $55.9 million for the fourth quarter of 2011, or $0.18 per diluted share.
CFO Howard Bradley Schiller, EVP and CFO Howard Bradley Schiller, and Executive Vice President and CFO Howard Bradley Schiller bought shares of VRX stock.
Tianyin Pharmaceutical Co. (TPI, Financial): CFO, Director and CBDO James Jiayuan Tong Bought 5,000 Shares
CFO, Director and CBDO of Tianyin Pharmaceutical Co. (TPI) James Jiayuan Tong bought 5,000 shares on 03/14/2012 at an average price of $0.85. TIANYIN is a manufacturer and supplier of modernized Traditional Chinese Medicine in China. Tianyin Pharmaceutical Co. has a market cap of $23.5 million; its shares were traded at around $0.87 with a P/E ratio of 2.4 and P/S ratio of 0.3.
Tianyin Pharmaceutical Inc. announced financial results for the second quarter of Fiscal Year 2012. Net Income was $1.7 million for the quarter ended Dec. 31, 2011, as compared to the net income of $1.5 million for the first quarter of fiscal 2012. Sales for the quarter ended Dec. 31, 2011 was $18.2 million, a decrease of 28.0% as compared to $25.3 million for the quarter ended Dec. 31, 2010, but a slight gain from the first quarter of fiscal 2012 which was $17.5 million.
CEO, 10% Owner Guoqing Jiang, and CFO, Director and CBDO James Jiayuan Tong bought shares of TPI stock.
For the complete list of stocks that bought by their CFOs, go to: Insider Buys.
